Compare Johnson & Johnson (JNJ) vs Vanguard Total World Stock Index Fund ETF (VT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Vanguard Total World Stock Index Fund ETF — how do they compare? Johnson & Johnson trades at $261.44 (market cap $618.09B), while Vanguard Total World Stock Index Fund ETF trades at $159.83 (market cap $101.70B). The key difference: Johnson & Johnson is far larger — about 6.1× Vanguard Total World Stock Index Fund ETF's market cap, and Johnson & Johnson pays a 2.09% dividend while Vanguard Total World Stock Index Fund ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Vanguard Total World Stock Index Fund ETF for 53 Days on average.
| JNJ | VT | |
|---|---|---|
Market Cap | $618.09B | $101.70B |
Volume | 6,050,983 | 1,783,794 |
Sector | Health | Broad Market / Factor |
52-Week High | $278.43 | $162.39 |
52-Week Low | $186.00 | $134.19 |
Typical Hold Time | 129 Days | 53 Days |
Enterprise Value | $646.37B | — |
Dividend Yield | 2.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $256.48, down 0.76% on the day, with the stock showing mixed technical signals amid a bearish overall trend. The company maintains strong fundamentals with $94.19B in 2025 revenue, 21.48% net income margin, and consistent earnings beats in recent quarters. Recent analyst coverage shows 52.5% buy ratings with a $286.53 consensus price target, while technical indicators point to key support at $248 and resistance at $258.
JNJ presents a compelling long-term investment case with robust profitability, diversified healthcare portfolio, and dividend stability, though near-term headwinds include patent expirations and competitive pressures. The stock's current valuation at 29.75 P/E appears reasonable given strong cash flow generation and pipeline innovation, with upside potential to analyst targets if execution continues.
VT trades at $158.73, down 0.57% on the day, with technical indicators showing a bearish bias as moving averages signal selling pressure. The ETF maintains its position as a comprehensive global equity vehicle with over 9,700 holdings and a 0.06% expense ratio. Recent news highlights VT's diversification benefits and cost competitiveness against peers like Schwab International Equity ETF and iShares MSCI World ETF.
The outlook remains favorable for long-term investors seeking broad global exposure, though near-term technical weakness suggests potential testing of support levels. Key risks include global market volatility and currency fluctuations, while institutional activity shows mixed positioning with recent sales by Barry Investment Advisors offset by new stakes from FAS Wealth Partners.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Vanguard Total World Stock Index Fund ETF
VT is a foundational, low-cost ETF that seeks to track the FTSE Global All Cap Index, providing exposure to nearly 10,000 stocks across developed and emerging markets worldwide, including the United States. It serves as a single-ticker solution for total global equity diversification, capturing approximately 98% of the world's investable market capitalization.
Read more on VT →
